Fosun Pharmaceutical (600196.SH) holding subsidiary plans to sell part of Gland Pharma's shares

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that on September 4, 2026, India time, Fosun Pharma Singapore, the company's holding subsidiary, sold a total of 9.897 million Gland Pharma shares through bulk transactions and centralized bidding (accounting for about 6.00% of the total number of Gland Pharma shares as of September 3, 2026). The total transaction consideration (before deducting transaction fees and taxes) was 27.996 billion Indian rupees (discounted contract of US$294 million), average price (before transaction fee and taxes) Approximately INR 2,828.78 per share (before commissions and taxes), a discount of about 2.72% from the closing price of the previous trading day (i.e. INR 2,907.90). The expected share transfer time for this transaction is September 7, 2026, India time.

Following the completion of this transaction, the Group still holds about 45.76% of Gland Pharma's shares (about 51.76% before this transaction) and is its controlling shareholder, and Gland Pharma is still a subsidiary within the scope of the Group's consolidated statements.

Proceeds from this transaction will mainly be used for the Group's R&D investment, share repurchases, and repayment of interest-bearing debts. Proceeds from the sale of this transaction will increase the Group's net assets; since this transaction is a transfer of part of the holding subsidiary's shares, the sale proceeds will not be included in the Group's income statement.